Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Agios Pharmaceuticals (NASDAQ:AGIO) are up nearly 10% today after the company before the opening bell announced the hiring of a well-regarded new chief medical officer.
So what: Agios brought Dr. Chris Bowden on board to oversee the company's clinical development and regulatory initiatives. Bowden has nearly two decades of experience in clinical drug development, most notably as vice president of oncology product development for Roche's Genentech subsidiary. His team developed several notable cancer treatments at Genentech, including Zelboraf, Tarceva, and Erivedge, according to Agios' press release.
Now what: Genentech's cancer treatments are among the world's best-sellers, and Bowden's developments have been among his former employer's most promising new drugs -- Zelboraf was named the Best New Drug of 2012 at the year's Scrip Awards. In 2008, the last year for which Genentech provides drug revenue breakdowns, Tarceva generated over $450 million in revenue.
If Bowden can develop even one drug on the same scale as his previous successes with Genentech, it stands to reason that Agios could find far more sales than it has today. However, this pop is still nothing more than a bet on future discoveries, and Bowden still has a long road ahead of him at Agios before he can replicate his Genentech successes.
Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
Alex Planes has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.